Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois.

The North American Menopause Society (NAMS) organized the Workshop on Normal Ranges for Estradiol in Postmenopausal Women from September 23 to 24, 2019, in Chicago, Illinois. The aim of the workshop was to review existing analytical methodologies for measuring estradiol in postmenopausal women and to assess existing data and study cohorts of postmenopausal women for their suitability to establish normal postmenopausal ranges. The anticipated outcome of the workshop was to develop recommendations for establishing normal ranges generated with a standardized and certified assay that could be adopted by clinical and research communities. The attendees determined that the term reference range was a better descriptor than normal range for estradiol measurements in postmenopausal women. Twenty-eight speakers presented during the workshop.

[1]  R. Santen,et al.  Systemic estradiol levels with low-dose vaginal estrogens , 2019, Menopause.

[2]  C. Reid,et al.  Testosterone and estrone increase from the age of 70 years; findings from the Sex Hormones in Older Women Study. , 2019, The Journal of clinical endocrinology and metabolism.

[3]  V. Beral,et al.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.

[4]  G. Anderson,et al.  Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. , 2019, JNCI cancer spectrum.

[5]  J. Cauley,et al.  Serum Sex Hormones and the Risk of Fracture Across the Menopausal Transition: Study of Women's Health Across the Nation. , 2019, The Journal of clinical endocrinology and metabolism.

[6]  R. Andrew,et al.  Current strategies for quantification of estrogens in clinical research , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  J. Manson,et al.  Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone? , 2018, International journal of cancer.

[8]  J. Manson,et al.  Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. , 2019, Menopause.

[9]  L. Brinton,et al.  Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status , 2018, Cancer Causes & Control.

[10]  W. Willett,et al.  Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study , 2018, PLoS medicine.

[11]  Julian H Barth,et al.  Indirect methods for reference interval determination – review and recommendations , 2018, Clinical chemistry and laboratory medicine.

[12]  James H. Liu,et al.  A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom , 2017, Journal of women's health.

[13]  D. Archer,et al.  A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom , 2017, Menopause.

[14]  J. Manson,et al.  Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study , 2017, Menopause.

[15]  J. Simon,et al.  A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review. , 2017, Maturitas.

[16]  T. Travison,et al.  Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe , 2017, The Journal of clinical endocrinology and metabolism.

[17]  F. Labrie,et al.  A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values , 2017, Hormone molecular biology and clinical investigation.

[18]  J. Henny,et al.  Recommendation for the review of biological reference intervals in medical laboratories , 2016, Clinical chemistry and laboratory medicine.

[19]  J. Botelho,et al.  Evaluation of an Isotope Dilution HPLC Tandem Mass Spectrometry Candidate Reference Measurement Procedure for Total 17-β Estradiol in Human Serum. , 2016, Analytical chemistry.

[20]  V. Henderson,et al.  Cognitive effects of estradiol after menopause , 2016, Neurology.

[21]  L. Kuller,et al.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[22]  L. Derogatis,et al.  Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. , 2015, The journal of sexual medicine.

[23]  P. Goode,et al.  Low-dose 17-β-estradiol cream for vaginal atrophy in a cohort without prolapse: Serum levels and vaginal response including tissue biomarkers associated with tissue remodeling. , 2015, Maturitas.

[24]  Frederick Naftolin,et al.  Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study , 2015, PLoS medicine.

[25]  Kannan Rangiah,et al.  Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography–tandem mass spectrometry , 2015, Steroids.

[26]  R. Santen.  Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels , 2015, Climacteric : the journal of the International Menopause Society.

[27]  D. Archer.  Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  Gretchen L. Gierach,et al.  Assay Reproducibility and Interindividual Variation for 15 Serum Estrogens and Estrogen Metabolites Measured by Liquid Chromatography–Tandem Mass Spectrometry , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[29]  Peter Kraft,et al.  Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  V. Henderson,et al.  Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause , 2013, Proceedings of the National Academy of Sciences.

[31]  Richard G. Moore,et al.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. , 2013, Gynecologic oncology.

[32]  S. Hankinson,et al.  Challenges to the measurement of estradiol: an endocrine society position statement. , 2013, Journal of Clinical Endocrinology and Metabolism.

[33]  A. LaCroix,et al.  Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. , 2013, Endocrine-related cancer.

[34]  L. Dennerstein,et al.  Hormone levels and cognitive function in postmenopausal midlife women , 2012, Neurobiology of Aging.

[35]  V. Henderson,et al.  Effects of endogenous and exogenous estrogen exposures in midlife and late-life women on episodic memory and executive functions , 2011, Neuroscience.

[36]  J. Waitzinger,et al.  Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets , 2010, Climacteric : the journal of the International Menopause Society.

[37]  H. Richter,et al.  Systemic Effects of Vaginally Administered Estrogen Therapy: A Review , 2010, Female pelvic medicine & reconstructive surgery.

[38]  E. Barrett-Connor,et al.  Endogenous oestrogens predict 4‐year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study , 2010, Clinical endocrinology.

[39]  R. Gut,et al.  Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet , 2008, Obstetrics and gynecology.

[40]  J. Chang-Claude,et al.  Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2008, Endocrine-related cancer.

[41]  J. Manson,et al.  A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[42]  A. Herlitz,et al.  Endogenous estrogen is not associated with cognitive performance before, during, or after menopause , 2007, Menopause.

[43]  T. Seeman,et al.  Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN). , 2007, Journal of women's health.

[44]  S. Cummings,et al.  Comparison of methods to measure low serum estradiol levels in postmenopausal women. , 2006, The Journal of clinical endocrinology and metabolism.

[45]  F. Berrino,et al.  Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women , 2004, International journal of cancer.

[46]  E. Dudley,et al.  Estrogen exposures and memory at midlife , 2003, Neurology.

[47]  Albert Hofman,et al.  Higher estrogen levels are not associated with larger hippocampi and better memory performance. , 2003, Archives of neurology.

[48]  T. Naessén,et al.  Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. , 2002, American journal of obstetrics and gynecology.

[49]  M. Conaway,et al.  Treatment of urogenital atrophy with low-dose estradiol: preliminary results , 2002, Menopause.

[50]  R. Shore,et al.  Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study , 2001, British Journal of Cancer.

[51]  E. Barrett-Connor,et al.  Cognitive Function and Endogenous Sex Hormones in Older Women , 1999, Journal of the American Geriatrics Society.

[52]  K. Yaffe,et al.  Serum Estrogen Levels, Cognitive Performance, and Risk of Cognitive Decline in Older Community Women , 1998, Journal of the American Geriatrics Society.

[53]  D. Ziegler,et al.  Vaginal Drug Delivery: The First Uterine Pass Effect a , 1997, Annals of the New York Academy of Sciences.